Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term Effect of Ozurdex in Refractory DME
NCT05736081Phase 4Completed
- Sponsor
- Asociación para Evitar la Ceguera en México
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in diabetic macular edema (DME), sponsored by Asociación para Evitar la Ceguera en México. Primary endpoint: Change in Central Retinal Thickness at 1 month. Started Feb 2018; status: completed.
02
Drugs
ozurdex
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05736081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05736081.